Abstracts tagged "outcome measures and rheumatoid arthritis (RA)"

Abstract Number: 356 • 2014 ACR/ARHP Annual Meeting
The Rheumatoid Arthritis Impact of Disease Score Is Associated with Disease Activity By Clinical, Laboratory and Ultrasonographic Measures: Validation in an inception Cohort of DMARD naïve Patients with Rheumatoid Arthritis
Lena Bugge Nordberg¹, Elisabeth Lie², Anna-Birgitte Aga¹, Marthe Thoresen Maehlen³, Inge Olsen C⁴, Till Uhlig⁴, Tore K. Kvien⁴, Espen A. Haavardsholm⁵ and the Arctic study Group⁵, ¹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The Rheumatoid arthritis impact of disease (RAID) score is a relatively new patient-derived composite score assessing the seven most important domains of the impact…
Abstract Number: 2287 • 2013 ACR/ARHP Annual Meeting
What Is The Internal Consistency Of The Disease Activity Score (DAS)-28 In Rheumatoid Arthritis Patients Treated In a Real–World Setting?
Andrew Chow¹, J. Carter Thorne², Regan Arendse³, Dalton E. Sholter⁴, Denis Choquette⁵, Isabelle Fortin⁶, Boulos Haraoui^5,7, Emmanouil Rampakakis^8,9, John S. Sampalis^8,9, Francois Nantel¹⁰, Allen J. Lehman¹¹, May Shawi¹² and Susan M. Otawa¹¹, ¹University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Rheumatology Associates, Edmonton, AB, Canada, ⁵Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁶Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁷Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The DAS-28 is used in clinical decision making and research as an outcome assessment for patients with RA. The tool measures clinical, patient centric…
Abstract Number: 2239 • 2013 ACR/ARHP Annual Meeting
Validation Of a Patient Reported Experience Measure In Patients With Rheumatoid Arthritis
Marwan Bukhari¹, Peter Jones², Ifeanyi Sargeant³, Maureen Cox⁴, Alison Elliott⁵, Suzanne Bullock⁶, Anne O'Brien² and Ailsa Bosworth⁷, ¹Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom, ²Keele University, Keele, United Kingdom, ³IS medical communications, Stafford, United Kingdom, ⁴Nuffield Orthopaedic centre, Oxford, United Kingdom, ⁵Roche Pharmaceuticals, Welwyn Garden City, United Kingdom, ⁶Lancaster University, Lancaster, United Kingdom, ⁷National Rheumatoid Arthritis Society, Maidenhead, United Kingdom
Background/Purpose: Improving patient experience is important in all diseases, but most important in patients with chronic rheumatic diseases like rheumatoid arthritis. To date there…
Abstract Number: 1972 • 2013 ACR/ARHP Annual Meeting
Erosion Case Definition and Scoring Reliability Exercise Using a New Outcome Measurement Tool, High-Resolution Peripheral Quantitative Computed Tomography, In Rheumatoid Arthritis
Cheryl Barnabe¹, Dominique Toepfer², Hubert Marotte³, Ellen-Margrethe Hauge⁴, Andrea Scharmga⁵, Roland Kocijan⁶, Sebastian Kraus⁷, Kresten K. Keller⁴, Joost de Jong⁸, Jeroen Williams⁸ and Stephanie Finzel⁷, ¹Medicine, Community Health Sciences, University of Calgary, Calgary, AB, Canada, ²Institute of Medical Physics, University of Erlangen-Nuremberg, Erlangen, Germany, ³Rheumatology Department, University Hospital of Saint-Étienne, Inserm U1059, Saint-Etienne, France, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁵Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁶Academic Teaching Hospital of Medical University Vienna, Vienna, Austria, ⁷Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Maastricht University, Maastricht, Netherlands
Background/Purpose: High-resolution peripheral quantitative computed tomography (HR-pQCT) is a novel imaging instrument for bony damage in rheumatoid arthritis (RA). Agreement on a case definition for…
Abstract Number: 1973 • 2013 ACR/ARHP Annual Meeting
Importance Of Hand Positioning In 3D Joint Space Morphology Assessment
Stephanie Boutroy¹, Elodie Hirschenhahn¹, Emile Youssof², Hervé Locrelle², Thierry Thomas², Roland Chapurlat³ and Hubert Marotte², ¹INSERM U1033 and University of Lyon, Hôpital Edouard Herriot, Lyon, France, ²INSERM U1059 and University Hospital, Hôpital Nord, Saint-Etienne, France, ³INSERM UMR 1033 and University of Lyon, Hôpital Edouard Herriot, Lyon, France
Background/Purpose: Precise quantification of joint space morphology (JSM) is an important factor for early diagnosis and monitoring of disease activity and therapeutic responses in rheumatoid…
Abstract Number: 2682 • 2013 ACR/ARHP Annual Meeting
Incidence Trends and Predictors Of Orthopedic Surgery In Patients With Rheumatoid Arthritis – Results From a Well Defined Population
Korosh Hekmat¹, Lennart Jacobsson², Jan-Åke Nilsson³, Minna Willim⁴, Martin Englund⁵, Ingemar F. Petersson⁶ and Carl Turesson², ¹Department of Clinical Sciences, Section of Rheumatology, Malmö, Lund University, Malmö, Sweden, ²Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Department of Clinical Sciences Malmö, Section of Rheumatology, Lund University, Malmö, Sweden, ⁵Department of Orthopedics, Clinical Sciences Lund,, Lund University, Lund, Sweden, ⁶Musculoskeletal Scienes, Department of Orthopedics, Clinical Sciences, Lund, Sweden
Background/Purpose: Orthopedic surgery is used effectively in many patients with severe rheumatoid arthritis (RA). The aim of modern pharmacologic treatment is to prevent joint destruction…
Abstract Number: 2371 • 2013 ACR/ARHP Annual Meeting
Is a Single Variable, The Swollen Joint Count, Valid As An Outcome Measure Separate From Being In An Index Measure? An Analysis From The Prospective, Biologic Treatment Registry Across Canada
J. Carter Thorne¹, Boulos Haraoui^2,3, William G. Bensen⁴, Algis Jovaisas⁵, Jude F. Rodrigues⁶, Denis Choquette², Alice V. Klinkhoff⁷, Emmanouil Rampakakis^8,9, John S. Sampalis^8,9, Francois Nantel¹⁰, Allen J. Lehman¹¹, May Shawi¹² and Susan M. Otawa¹¹, ¹Southlake Regional Health Centre, Newmarket, ON, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ⁴Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁵Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁶Rheumatology, Windsor, ON, Canada, ⁷The Mary Pack Arthritis Ctr, Vancouver, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The importance of joint counts as measures of synovitis is reflected in their prominence in all major clinical composite indices, the Disease Activity Score…
Abstract Number: 2279 • 2013 ACR/ARHP Annual Meeting
Assessment Of Global Disease Activity In Rheumatoid Arthritis By Patients and Physicians: Cultural Differences Among Countries In The Meteor Database
E. Gvozdenovic¹, R. Wolterbeek², C.F. Allaart¹, Claiton Brenol³, Arvind Chopra⁴, Maxime Dougados⁵, Paul Emery⁶, D. van der Heijde⁷, T.W.J. Huizinga¹, Jonathan Kay⁸, Emilio Martín Mola⁹, Robert J. Moots¹⁰, José A. P. Da Silva¹¹, Josef S. Smolen¹², Douglas J. Veale¹³ and R. Landewe¹⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Biostatistics, Leiden University Medical Center, Leiden, Netherlands, ³Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, ⁴Rheumatology, Center for Rheumatic Diseases, Pune, India, ⁵Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁶Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁹Rheumatology. La Paz Hospital. IdiPaz, Madrid, Spain, ¹⁰Clinical Sciences Centre, University of Liverpool, Liverpool, United Kingdom, ¹¹Serviço de Reumatologia, Centro Hospitalar e Universitário de Coimbra – Hospitais da Universidade de Coimbra, E.P.E., Coimbra, Portugal, ¹²Medical University of Vienna, Vienna, Austria, ¹³Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ¹⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Dissonant perceptions of disease activity between rheumatoid arthritis (RA) patients and their rheumatologists may influence treatment decisions. The discordance between patient's and physician's global…
Abstract Number: 2609 • 2012 ACR/ARHP Annual Meeting
Construct and Criterion Validity of Several Proposed DAS28 Based Rheumatoid Arthritis Flare Criteria: A Cohort Validation Study
Aatke van der Maas¹, Elisabeth Lie², Robin Christensen³, Ernest Choy⁴, Yaël A. de Man⁵, Piet L.C.M. van Riel⁶, Thasia G. Woodworth⁷ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁵Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Medicine, Division of Rheumatology, Visiting Clinical Researcher, Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: To enable consistent assessment of impact of tapering, withdrawal and dose optimization strategies, there is an increasing need for validated measures of flare in…
Abstract Number: 2134 • 2012 ACR/ARHP Annual Meeting
The Changed Prognosis of Patients with Early Rheumatoid Arthritis
Karin Britsemmer¹ and Dirkjan van Schaardenburg², ¹Rheumatology, Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
The Changed Prognosis of Patients with Early Rheumatoid Arthritis Background/Purpose: The treatment of rheumatoid arthritis (RA) has changed greatly during the past fifteen to twenty…
Abstract Number: 2103 • 2012 ACR/ARHP Annual Meeting
Reliability of DAS28 in Rheumatoid Arthritis When Based On Patient Self-Assessment of Tender and Swollen Joints
Ole Rintek Madsen and Cecilie Heegaard, Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark
Background/Purpose: Clinical assessment of disease activity is a routine procedure when evaluating individual rheumatoid arthritis (RA) patients in daily practice. Swollen joint count (SJC) and…
Abstract Number: 2106 • 2012 ACR/ARHP Annual Meeting
Patient Characteristics Associated with Discrepancies in Evaluator-Reported and Patient-Reported Outcomes in U.S. Veterans with Rheumatoid Arthritis
Archana Jain¹, Rebecca Belsom¹, Jeffrey R. Curtis², Shuo Yang³, Ted R. Mikuls⁴, Lang Chen⁵ and Angelo L. Gaffo⁶, ¹Rheumatology, University of Alabama, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Validated tools that incorporate evaluator and patient reported outcomes (PROs) are used for guiding therapy in patients with rheumatoid arthritis (RA). PROs used in…
Abstract Number: 2109 • 2012 ACR/ARHP Annual Meeting
Discrepancy Between Patient and Physician Global Assessments Over Time in Early Rheumatoid Arthritis
Pooneh Akhavan¹, Vivian P. Bykerk², Juan Xiong³, Janet E. Pope⁴, Boulos Haraoui⁵, J. Carter Thorne⁶, Gilles Boire⁷, Carol A. Hitchon⁸, Diane Tin⁹, Edward Keystone¹⁰ and CATCH¹¹, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ⁵Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Toronto
Background/Purpose: Discrepancy between patient (PGA) and physician (MDGA) global assessments in RA can adversely affect therapeutic decisions in many cases. The purpose of this study…
Abstract Number: 1698 • 2012 ACR/ARHP Annual Meeting
Predictors of Discontinuation of Biologics in 2,281 US Patients with Rheumatoid Arthritis
Sofia Ramiro¹, Frederick Wolfe², David J. Harrison³, George Joseph³, David H. Collier³, Désirée van der Heijde⁴, Robert Landewé⁵ and Kaleb Michaud⁶, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Amgen Inc., Thousand Oaks, CA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Identifying predictors of discontinuation of biologic treatment for Rheumatoid Arthritis (RA) has clinical and research importance given the chronicity of RA and high costs…
Abstract Number: 1311 • 2012 ACR/ARHP Annual Meeting
A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate
Roy Fleischmann¹, Steven De Bruyn², Christian Duby², Katrien Verschueren³, Judith Baumeister⁴, Laura Sargentini-Maier⁵, Cedric Ververken⁶ and Josefin-Beate Holz⁷, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ³Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ⁴Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ⁵Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ⁶Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁷Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: Ozoralizumab (ATN-103), a novel TNFα inhibitor, is a trivalent, bispecific Nanobody® that potently neutralises TNF and binds to human serum albumin to increase its…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].